Visit
Zanubrutinib was approved by the Food and Drug Administration (FDA) on the 19th of January 2023, for the treatment of…
VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…
Learn how to build a social media strategy effectively and appropriately alongside your clinical practice. Independent medical support by Janssen…
Learn how to engage on Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals
VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…
Learn about the importance of performing genomic testing in CLL and how this impacts diagnosis, prognosis and treatment decisions.
Learn how to use Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals
Bruton’s tyrosine kinase (BTK) inhibitors fulfill an increasingly important role in the treatment of patients with B-cell malignancies including chronic…
Bruton’s tyrosine kinase (BTK) plays an essential role in the B-cell antigen receptor signaling pathway and is required for the…
VJHemOnc brings you roundtable discussions with leading hematological experts in myeloma, AML, CLL, ALL, lymphoma, MDS and MPNs.
VJHemOnc is proud to present the SOHO Italy 2020 Virtual Meeting, which took place on the 22nd-24th of September 2020.
VJHemOnc was official Media Partner for the ERIC 2020 Virtual Meeting, New Frontiers in CLL Research, which took place on 1-3…
The U.S. Food and Drug Administration (FDA) has approved the first and only assay – clonoSEQ®, to screen and assess…
VJHemOnc are excited to present late-breaking abstracts and key trial updates announced at this year’s virtual EHA meeting!
Following positive results gleaned from the E1912 trial (NCT02048813), the U.S. Food and Drug Administration (FDA) has expanded the indication…
Chimeric antigen receptor T-cell (CAR-T) therapies have proven particularly successful in hematological malignancies. However, CAR T-cells still underperform when used…
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter